Proprietary Business Strategy

> Proprietary History and Strategy

In 1997, Barr announced plans to extend its pharmaceutical research and development activities into proprietary product development.

In October 2001, after its acquisition of Duramed Pharmaceuticals, Inc., Barr dramatically strengthened its commitment to proprietary product development with the formation of Barr Research, Inc. In August 2005, Barr Research, Inc. became Duramed Research, Inc. The Duramed Research team has extensive brand product experience in clinical trials, toxicology, regulatory affairs, pharmacokinetics, statistics and medical writing. The team's primary focus is the expansion of a robust strategic proprietary product portfolio through the submission of New Drug Applications (NDAs).